B7-H4 antibodies and methods of use thereof

US11814431B2 · kind B2 · utility

Assignee

• Five Prime Therapeutics, Inc. · US

Inventors

• Charles Kaplan · South San Francisco, US
• Derrick Houser · San Francisco, US
• Luis Borges · Seattle, US
• Gloria Brattich · San Francisco, US
• David Bellovin · San Jose, US
• Felicia Kemp · San Jose, US
• Majid Ghoddusi · Walnut Creek, US
• Nels P. Nielson · Cambridge, US
• Kathy Miller · San Francisco, US
• Maike Schmidt · San Francisco, US

Key dates

• Filing date: Mar 10, 2020
• Grant date: Nov 14, 2023
• Expiry date: May 7, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.